Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - patients


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.6018
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.

Matthew H. Taylor · Justin F. Gainor · Mimi I-Nan Hu · Viola W. Zhu · Gilberto Lopes · Sophie Leboulleux · Marcia S. Brose · Martin Schuler · Daniel W. Bowles · Dong-Wan Kim · Christina S. Baik · Elena Garralda · Chia-Chi Lin · Douglas Adkins · Debashis Sarker · Giuseppe Curigliano · Hui Zhang · Corinne Clifford · Christopher D. Turner · Vivek Subbiah ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9000
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Kazuhiko Nakagawa · Edward B. Garon · Takashi Seto · Makoto Nishio · Santiago Ponce Aix · Chao-Hua Chiu · Keunchil Park · Silvia Novello · Ernest Nadal · Fumio Imamura · Kiyotaka Yoh · Jin-Yuan Shih · Kwok Hung Au · Denis Moro-Sibilot · Sotaro Enatsu · Annamaria Zimmermann · Bente Frimodt-Moller · Carla M. Visseren Grul · Martin Reck ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.3501
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Timothy Iveson · Alberto Sobrero · Takayuki Yoshino · Ioannis Sougklakos · Fang-Shu Ou · Jeffery P. Meyers · Qian Shi · Mark P Saunders · Roberto Labianca · Takeharu Yamanaka · Ioannis Boukovinas · Niels Henrik Hollander · Valter Torri · Kentaro Yamazaki · Vassilis Georgoulias · Sara Lonardi · Andrea Harkin · Gerardo Rosati · James Paul ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.129
Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).

Hiroki Hara · Hirokazu Shoji · Daisuke Takahari · Taito Esaki · Nozomu Machida · Kengo Nagashima · Kazunori Aoki · Kazufumi Honda · Takahiro Miyamoto · Narikazu Boku · Ken Kato ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.2514
A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

Laura Quan Man Chow · Justin F. Gainor · Nehal J. Lakhani · Hyun Cheol Chung · Keun-Wook Lee · Jeeyun Lee · Patricia LoRusso · Yung-Jue Bang · F. Stephen Hodi · Philip Fanning · Yonggang Zhao · Feng Jin · Hong Wan · Jaume Pons · Sophia Randolph · Wells A. Messersmith ·

Medicine
PDF

RESULTS Of the 302,140 patients who underwent sleeve gastrectomy or laparoscopic gastric bypass in 2015-2016, a total of 4947 (1.

Perioperative outcomes of bariatric surgery in the setting of chronic steroid use: an MBSAQIP database analysis. [10.1016/J.SOARD.2019.02.007]


Methods CAPD patients were recruited from the chronic kidney disease and CAPD Clinic of University Hospital.

Associated factors for depressive disorder in patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis [10.2147/TCRM.S186394]


Clinical features and outcome differences among nonhistaminergic vs histaminergic angioedema patients in the emergency department (ED) are poorly characterized.

Clinical Features and Outcomes Associated with Angioedema in the Emergency Department [10.5811/westjem.2019.6.42852]


Clinical trials have shown that lomitapide reduces low-density-lipoprotein cholesterol levels by around 40% in homozygous familial hypercholesterolemia patients on treatment with statins with or without low-density-lipoprotein apheresis, with an acceptable safety and tolerance profile.

Lomitapide: a review of its clinical use, efficacy, and tolerability [10.2147/CE.S174169]


Future studies should focus on targeting patients who are most likely to benefit from this service.

Effect of Pharmacy-Driven Bedside Discharge Medication Delivery Program on Day 30 Hospital Readmission [10.1177/0897190019825961]


Highly Related Keywords from patients

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals